Page last updated: 2024-09-04

atrasentan and Bladder Cancer

atrasentan has been researched along with Bladder Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bolenz, C; Bremer, C; Eltze, E; Herrmann, E; Hertle, L; Persigehl, T; Tiemann, A; Wülfing, C	1

Other Studies

1 other study(ies) available for atrasentan and Bladder Cancer

Article	Year
Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:10 Topics: Animals; Atrasentan; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Mitosis; Necrosis; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymus Gland; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2009

Article

Year

Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model.

Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:10

Topics: Animals; Atrasentan; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Mitosis; Necrosis; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymus Gland; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2009